BRENNEN

Industries / Frontier science

Cell and gene therapy

Cell and gene therapy makes medicines that add, repair or switch off genes in a patient's cells, or that are themselves living cells, often the patient's own, changed in a lab and given back.

1990

On 14 September 1990 researchers at the US National Institutes of Health (NIH) began the first clinical trial of gene therapy, adding a working ADA gene to the white blood cells of a 4-year-old girl with an inherited immune disease, ADA-SCID.

genome.gov

25

Milestones achieved across 4 domains.

9

To watch for: announced, not yet confirmed outside.

8

Open deliverables. Nobody has shipped them.

In one minute

Where it started

Cell therapy grew out of bone marrow transplants: in 1968 teams in Minnesota and Wisconsin moved marrow between matched brothers and sisters. Gene therapy began in 1990, when NIH researchers added a working gene to a child's immune cells, the same year Steven Rosenberg's team reported tracking gene-marked cells in people. In 1989 a lab in Israel built the chimeric antigen receptor, the design behind today's CAR-T cancer medicines.

Where it stands

On 30 October 2026 the FDA's list of approved cell and gene therapy products had 55 entries, from cord-blood stem cells to CAR-T cells and one-time gene therapies. Single doses are priced in the millions of dollars, and some approved products have been withdrawn because too few patients or payers took them up. Regulators now accept smaller studies for very rare diseases, while FDA officials have asked new CAR-T medicines to beat existing treatment in randomised trials.

What is open

Much of what the field knows sits in scattered papers, company filings and review documents: how long patients wait for a dose, how often making one fails, which trials were stopped and why, what each approval rested on, and which payment deals exist. Each could become an open, checked table built from public sources, with an AI model drafting entries and a person checking them. Where these treatments can be given is mapped for parts of the US and England only; by the World Health Organization's count about 515,000 babies are born with sickle cell disease each year, about 80% of them in sub-Saharan Africa, where a Nigerian patient leader told SciDev.Net in 2026 that gene therapy "exists only on paper".

Domains

AchievedWatch forOpen

Advances to build with

1 research note

Open in cell and gene therapy

3 of 8 open deliverables

Open · Living cell medicines

CAR-T trials and their results

A free, downloadable table with one row per registered CAR-T or CAR-NK trial, giving the target, the disease, whether the cells are the patient's or a donor's, the receptor's signalling parts where they are reported, the country, the trial's status, and a link to any posted or published result, or "none found". The table refreshes monthly.

Built with what exists

The ClinicalTrials.gov API (version 2) and the Chinese and EU trial registries; the Europe PMC API for papers; a large language model such as Claude to draft each row from the papers, with a person checking every field against its source. The note "Findings that cite notes" covers an agent that cites the source behind each finding, the habit this table needs.

Credit · unclaimed

Open · Making each dose

A public vein-to-vein table

A free table of vein-to-vein time, the days from collecting a patient's cells to infusing the finished dose, for every approved CAR-T and T-cell product. Each row gives product, disease, country, year, the median reported, the exact definition the source used, and a link.

Built with what exists

The Europe PMC and ClinicalTrials.gov APIs; FDA and EMA product documents read with pdftotext; a large language model such as Claude to find candidate figures, with a person confirming each one; a CSV in a public repository.

Credit · unclaimed

Open · Testing and approval

A running clinical-hold log

A public table of every clinical hold, an FDA order that stops a trial, placed on a cell or gene therapy trial since 2020, as disclosed in company filings and press releases. Each row gives the product type, the dates the hold was placed and lifted, the stated reason (patient harm, manufacturing, animal data) and the quoted sentence it came from. The table refreshes monthly.

Built with what exists

The US Securities and Exchange Commission's EDGAR full-text search to find "clinical hold" in company filings; company press-release pages; an AI model such as Claude to pull dates and reasons with the quoted sentence; a person checking each row; a CSV file in a public GitHub repository. The note "Findings that cite notes" (Cursor's agent kit) covers an agent built to cite the source behind each finding.

Credit · unclaimed